<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Gastric and <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> are among the most common <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> worldwide and cause serious <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality </plain></SENT>
<SENT sid="1" pm="."><plain>Both epigenetic and genetic disruptions of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor genes (TSGs) are frequently involved in their pathogenesis </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we studied the epigenetic and genetic alterations of a novel TSG-PCDH17 and its functions in the pathogenesis of these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We found that PCDH17 was frequently silenced and methylated in almost <z:hpo ids='HP_0000001'>all</z:hpo> gastric and <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumour</z:e> cell lines as well as in âˆ¼95% of <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumours</z:e>, but not in <z:mpath ids='MPATH_458'>normal</z:mpath> gastric and colonic mucosa </plain></SENT>
<SENT sid="4" pm="."><plain>Moreover, its deletion was detected in only 18% of gastric and 12% of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> tissues, suggesting that epigenetic and genetic inactivation of PCDH17 are both involved in gastric and colorectal <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">tumourigenesis</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>PCDH17 protein expression was significantly correlated with low <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> stage and less lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> of gastric and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients, indicating its potential as a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> marker </plain></SENT>
<SENT sid="6" pm="."><plain>Restoring PCDH17 expression inhibited <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cell growth in vitro and in vivo through promoting <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, as evidenced by increased TUNEL staining and caspase-3 activation </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, PCDH17-induced autophagy, along with increased numbers of <z:hpo ids='HP_0003736'>autophagic vacuoles</z:hpo> and up-regulated autophagic proteins Atg-5, Atg-12 and LC3B II </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, PCDH17 acts as a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor, exerting its anti-proliferative activity through inducing <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and autophagy, and is frequently silenced in gastric and <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>PCDH17 methylation is a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-specific event that could serve as an epigenetic biomarker for these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
</text></document>